Developer docs
API playgroundTry for free, no card

Search company profiles

Bodyport

Full company profile

uuid0000eeu

Namestring
Bodyport
Legal namestring
Bodyport Inc.
Websiteurl
bodyport.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Bodyport is a San Francisco-based, venture-backed digital health company founded in 2015 that has built an FDA-cleared Fluid Management Platform centered on the Bodyport Cardiac Scale and the Congestion Index algorithm. The Cardiac Scale is a non-invasive device that captures hemodynamic biomarkers through a patient's feet in under 30 seconds during a normal daily weighing step, transmitting data over a cellular connection to care teams — eliminating the need for Bluetooth pairing, Wi-Fi, smartphones, or surgical implants. The Congestion Index combines multiple hemodynamic biomarkers into a composite metric that, in the SCALE-HF 1 clinical study (329 enrolled participants across 8 sites, 238 patient-years of follow-up, published in the Journal of Cardiac Failure), detected 70% of heart failure events versus 35% for conventional weight-based monitoring, with 14 days of average lead time and 38% fewer false alerts.

The platform is delivered through three integrated surfaces: a Care Portal clinical dashboard for triage and intervention, a Patient Portal app for self-management, and a robust API for EHR integration. The system is HIPAA-compliant and SOC 2 Type 2 certified, and includes built-in support for Remote Patient Monitoring (RPM) billing codes to streamline provider reimbursement. Bodyport generates revenue through hardware sales of the Cardiac Scale and subscription-based RPM services sold via enterprise field sales to health systems and healthcare providers.

Bodyport serves U.S. health systems and providers managing heart failure and cardiorenal patient populations, with clinical research and deployment partnerships involving Geisinger, Stanford, Duke, Yale, Brigham and Women's Hospital, the Duke Clinical Research Institute, Keck Medical Center of USC, and Boehringer Ingelheim. The company has raised approximately $15.8 million in total disclosed venture funding across rounds led by investors including Playground Global, Initialized Capital, Boehringer Ingelheim Venture Fund, Rock Health, Kapor Capital, and Y Combinator. Leadership includes CEO John Lipman (appointed June 2022), co-founder Corey Centen as President and CTO, CCO Amit Rushi, and a board chaired by Phyllis Whiteley, Ph.D. (Playground Global).

Short descriptiontext

Bodyport is a San Francisco digital health company that has developed the FDA-cleared Cardiac Scale and Congestion Index algorithm to non-invasively detect worsening heart failure in patients at home, serving U.S. health systems and heart failure patients through remote patient monitoring.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
heart failure monitoring, remote patient monitoring, cardiac biomarker platform, non-invasive diagnostics, digital health devices
Industry4 codes
PRIMARYHLACAPAI
Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLALAFAA
Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYHLACAPAB
Connected Medical Devices & Wearables (Sensors, Patches, Implantables)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLALABAF
Chronic Care & Remote Patient Monitoring (RPM) Platforms
Healthcare & Life Sciences/Telehealth Platforms/Provider-Integrated Virtual Care Platforms (Health Systems/Clinics)
Product category
Remote Cardiac Monitoring
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Remote Patient Monitoring (RPM) Billing
TypeSubscription Recurring
Description

Platform supports RPM billing codes enabling healthcare providers to bill for remote monitoring services. The company generates revenue through health system partnerships and reimbursement for remote monitoring services.

bodyport.com
2Hardware Device Sales
TypeHardware Sales
Description

Sale of Bodyport Cardiac Scale devices to health systems and healthcare providers for patient use.

bodyport.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Bodyport Cardiac Scale
Description

FDA-cleared scale device that non-invasively measures hemodynamic biomarkers through a patient's feet to assess heart function and fluid status.

bodyport.com
+3 more records
Core offering1 text field

Bodyport develops and sells the FDA 510(k)-cleared Bodyport Cardiac Scale, a non-invasive connected scale that captures hemodynamic biomarkers through a patient's feet in under 30 seconds and transmits the data via cellular connection. It combines the hardware with the Congestion Index algorithm and a connected software platform (Care Portal for clinicians and Patient Portal for patients) to detect early signs of worsening heart failure and enable proactive in-home care.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Detects 70% of heart failure events vs 35% for weight-based monitoring
+3 more records
Product overview1 text field

Bodyport is a biomarker-guided digital therapeutics company offering a Fluid Management Platform centered on the FDA-cleared Bodyport Cardiac Scale hardware and the Congestion Index algorithm. The platform includes the Care Portal (Clinical Dashboard) for healthcare providers and a Patient Portal for at-home monitoring. Patients step barefoot on the Cardiac Scale for ~30 seconds daily, with hemodynamic data automatically transmitted via cellular to care teams. The Congestion Index algorithm analyzes multiple biomarkers to detect worsening heart failure with 70% sensitivity (vs 35% for weight-based monitoring).

Product and service3 records
1Bodyport Cardiac Scale
CategoryRemote cardiac monitoring hardware
Description

FDA-cleared, non-invasive connected scale that measures hemodynamic biomarkers through a patient's feet in under 30 seconds using advanced sensors and proprietary algorithms, and transmits the data over a cellular connection to care teams for at-home heart failure and fluid status monitoring. Sold to health systems and healthcare providers for patient use.

2Congestion Index
CategoryPredictive biomarker algorithm
Description

Advanced composite algorithm that combines multiple hemodynamic biomarkers captured by the Bodyport Cardiac Scale into a single metric for early detection of worsening heart failure; demonstrated 70% heart failure event detection vs 35% for weight-based monitoring in the SCALE-HF 1 study. Delivered to health systems as part of the Bodyport platform.

3Bodyport Care Portal (Clinical Dashboard)
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Leading health system partner collaborating with Bodyport on heart failure care solutions. Part of visible logo display on website indicating active partnership.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic medical center partner in research and clinical validation of Bodyport technology.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Leading clinical research organization partnering on SCALE-HF studies and heart failure research.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic partner in research and clinical validation of Bodyport technology.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Leading academic medical center partner in research and clinical studies.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic partner with Dr. Adam DeVore serving as SCALE-HF principal investigator.

7Boehringer Ingelheim
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Pharmaceutical partner collaborating on cardiorenal conditions research and solutions.

bodyport.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Abbott
TypeDirect peer
Description

Markets the CardioMEMS HF System, the leading FDA-approved implantable hemodynamic monitor for heart failure. CardioMEMS directly competes with Bodyport's cardiac scale by providing continuous PA pressure data to clinicians, though it requires an implantable sensor while Bodyport is non-invasive.

TypeBroad incumbent
Description

A leading cardiovascular device company with hemodynamic monitoring expertise (Swan-Ganz catheters, FloTrac, Acumen IQ). Comparable as a broader incumbent in cardiac diagnostics and monitoring, though Edwards primarily operates in acute and surgical care settings rather than at-home RPM.

TypeDirect peer
Description

Develops a miniaturized, implantable left-atrial pressure sensor for heart failure patients. Direct competitor in next-generation hemodynamic monitoring for HF; competing modality (implantable vs. Bodyport's non-invasive scale) but same target use case and clinical claim.

TypeEmerging player
Description

Develops non-invasive, AI-enabled cardiac function assessment platforms. Closely comparable to Bodyport in using non-invasive sensors plus proprietary algorithms to evaluate cardiac performance, though Sensydia targets pulmonary and cardiac acoustic biomarkers.

TypeDirect peer
Description

Combines digital stethoscopes with AI algorithms for cardiac and pulmonary disease detection. Comparable as a hardware-plus-AI cardiac diagnostics company targeting clinicians, with FDA-cleared AI algorithms for heart murmur and AFib detection.

TypeDirect peer
Description

Provider of ambulatory cardiac monitoring (Zio long-term continuous ECG patch) with AI-based arrhythmia detection. Direct peer in connected cardiac monitoring services with established reimbursement and IDN relationships, though focused on arrhythmias rather than HF congestion.

TypeDirect peer
Description

Maker of KardiaMobile personal ECG devices with AI-based cardiac monitoring. Comparable as a connected, AI-driven cardiac monitoring company with both consumer and clinical channels targeting chronic cardiac condition management.

TypeBroad incumbent
Description

AI-driven non-invasive cardiac diagnostics (FFR-CT) for coronary artery disease. Broader incumbent in non-invasive, imaging- and AI-based cardiac diagnostics used by cardiologists and health systems for decision support.

TypeBroad incumbent
Description

Connected consumer health devices including smart scales, blood pressure monitors, and sleep mats. Adjacent competitor in the connected home-health device category, though Withings targets general wellness rather than clinical HF management.

TypeEmerging player
Description

AI-driven coronary CT angiography analysis for plaque and ischemia assessment. Comparable as an emerging AI-native cardiac diagnostics company with strong health-system commercial traction and category-defining clinical evidence.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bodyport

Remote Cardiac Monitoringbodyport.com

Bodyport is a San Francisco digital health company that has developed the FDA-cleared Cardiac Scale and Congestion Index algorithm to non-invasively detect worsening heart failure in patients at home, serving U.S. health systems and heart failure patients through remote patient monitoring.

What Bodyport does

Bodyport is a San Francisco-based, venture-backed digital health company founded in 2015 that has built an FDA-cleared Fluid Management Platform centered on the Bodyport Cardiac Scale and the Congestion Index algorithm. The Cardiac Scale is a non-invasive device that captures hemodynamic biomarkers through a patient's feet in under 30 seconds during a normal daily weighing step, transmitting data over a cellular connection to care teams — eliminating the need for Bluetooth pairing, Wi-Fi, smartphones, or surgical implants. The Congestion Index combines multiple hemodynamic biomarkers into a composite metric that, in the SCALE-HF 1 clinical study (329 enrolled participants across 8 sites, 238 patient-years of follow-up, published in the Journal of Cardiac Failure), detected 70% of heart failure events versus 35% for conventional weight-based monitoring, with 14 days of average lead time and 38% fewer false alerts.

The platform is delivered through three integrated surfaces: a Care Portal clinical dashboard for triage and intervention, a Patient Portal app for self-management, and a robust API for EHR integration. The system is HIPAA-compliant and SOC 2 Type 2 certified, and includes built-in support for Remote Patient Monitoring (RPM) billing codes to streamline provider reimbursement. Bodyport generates revenue through hardware sales of the Cardiac Scale and subscription-based RPM services sold via enterprise field sales to health systems and healthcare providers.

Bodyport serves U.S. health systems and providers managing heart failure and cardiorenal patient populations, with clinical research and deployment partnerships involving Geisinger, Stanford, Duke, Yale, Brigham and Women's Hospital, the Duke Clinical Research Institute, Keck Medical Center of USC, and Boehringer Ingelheim. The company has raised approximately $15.8 million in total disclosed venture funding across rounds led by investors including Playground Global, Initialized Capital, Boehringer Ingelheim Venture Fund, Rock Health, Kapor Capital, and Y Combinator. Leadership includes CEO John Lipman (appointed June 2022), co-founder Corey Centen as President and CTO, CCO Amit Rushi, and a board chaired by Phyllis Whiteley, Ph.D. (Playground Global).

Bodyport firmographics

Firmographics
Name
Bodyport
Legal name
Bodyport Inc.
Website
https://bodyport.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Bodyport is a San Francisco digital health company that has developed the FDA-cleared Cardiac Scale and Congestion Index algorithm to non-invasively detect worsening heart failure in patients at home, serving U.S. health systems and heart failure patients through remote patient monitoring.
Ownership category
akta.pro rank

Bodyport industry classification

Industry
Product category
Remote Cardiac Monitoring
akta.pro industry
PRIMARYHLACAPAI
Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLALAFAA
Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYHLACAPAB
Connected Medical Devices & Wearables (Sensors, Patches, Implantables)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLALABAF
Chronic Care & Remote Patient Monitoring (RPM) Platforms
Healthcare & Life Sciences/Telehealth Platforms/Provider-Integrated Virtual Care Platforms (Health Systems/Clinics)

Keywords

  • Heart failure monitoring
  • Remote patient monitoring
  • Cardiac biomarker platform
  • Non-invasive diagnostics
  • Digital health devices

Where Bodyport is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Bodyport business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Remote Patient Monitoring (RPM) Billing: Platform supports RPM billing codes enabling healthcare providers to bill for remote monitoring services. The company generates revenue through health system partnerships and reimbursement for remote monitoring services.
  2. Hardware Device Sales: Sale of Bodyport Cardiac Scale devices to health systems and healthcare providers for patient use.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Bodyport product offering

Product offering

Core offering

Bodyport develops and sells the FDA 510(k)-cleared Bodyport Cardiac Scale, a non-invasive connected scale that captures hemodynamic biomarkers through a patient's feet in under 30 seconds and transmits the data via cellular connection. It combines the hardware with the Congestion Index algorithm and a connected software platform (Care Portal for clinicians and Patient Portal for patients) to detect early signs of worsening heart failure and enable proactive in-home care.

Product overview

Bodyport is a biomarker-guided digital therapeutics company offering a Fluid Management Platform centered on the FDA-cleared Bodyport Cardiac Scale hardware and the Congestion Index algorithm. The platform includes the Care Portal (Clinical Dashboard) for healthcare providers and a Patient Portal for at-home monitoring. Patients step barefoot on the Cardiac Scale for ~30 seconds daily, with hemodynamic data automatically transmitted via cellular to care teams. The Congestion Index algorithm analyzes multiple biomarkers to detect worsening heart failure with 70% sensitivity (vs 35% for weight-based monitoring).

Differentiator

Problem solved

Functional benefit

Brands

  • Bodyport Cardiac Scale: FDA-cleared scale device that non-invasively measures hemodynamic biomarkers through a patient's feet to assess heart function and fluid status.
  • Congestion Index
  • Bodyport Care Portal
  • Bodyport Patient App

Products and services

  • Bodyport Cardiac Scale FDA-cleared, non-invasive connected scale that measures hemodynamic biomarkers through a patient's feet in under 30 seconds using advanced sensors and proprietary algorithms, and transmits the data over a cellular connection to care teams for at-home heart failure and fluid status monitoring. Sold to health systems and healthcare providers for patient use.
  • Congestion Index Advanced composite algorithm that combines multiple hemodynamic biomarkers captured by the Bodyport Cardiac Scale into a single metric for early detection of worsening heart failure; demonstrated 70% heart failure event detection vs 35% for weight-based monitoring in the SCALE-HF 1 study. Delivered to health systems as part of the Bodyport platform.
  • Bodyport Care Portal (Clinical Dashboard)

Quantifiable outcome

  • Detects 70% of heart failure events vs 35% for weight-based monitoring
  • +3 more outcomes

Companies that use Bodyport

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Bodyport technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Bodyport partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core.

  • GeisingercoreStrategic or Co-development PartnerLeading health system partner collaborating with Bodyport on heart failure care solutions. Part of visible logo display on website indicating active partnership.
  • StanfordcoreStrategic or Co-development PartnerAcademic medical center partner in research and clinical validation of Bodyport technology.
  • Duke Clinical Research Institute (DCRI)coreStrategic or Co-development PartnerLeading clinical research organization partnering on SCALE-HF studies and heart failure research.
  • YalecoreStrategic or Co-development PartnerAcademic partner in research and clinical validation of Bodyport technology.
  • Brigham and Women's HospitalcoreStrategic or Co-development PartnerLeading academic medical center partner in research and clinical studies.
  • Duke UniversitycoreStrategic or Co-development PartnerAcademic partner with Dr. Adam DeVore serving as SCALE-HF principal investigator.
  • Boehringer IngelheimcoreStrategic or Co-development PartnerPharmaceutical partner collaborating on cardiorenal conditions research and solutions.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Bodyport competitors and assessment

Company assessment

Direct peers

  • Abbott: Markets the CardioMEMS HF System, the leading FDA-approved implantable hemodynamic monitor for heart failure. CardioMEMS directly competes with Bodyport's cardiac scale by providing continuous PA pressure data to clinicians, though it requires an implantable sensor while Bodyport is non-invasive.
  • Vectorious Medical Technologies: Develops a miniaturized, implantable left-atrial pressure sensor for heart failure patients. Direct competitor in next-generation hemodynamic monitoring for HF; competing modality (implantable vs. Bodyport's non-invasive scale) but same target use case and clinical claim.
  • Eko Health: Combines digital stethoscopes with AI algorithms for cardiac and pulmonary disease detection. Comparable as a hardware-plus-AI cardiac diagnostics company targeting clinicians, with FDA-cleared AI algorithms for heart murmur and AFib detection.
  • iRhythm Technologies: Provider of ambulatory cardiac monitoring (Zio long-term continuous ECG patch) with AI-based arrhythmia detection. Direct peer in connected cardiac monitoring services with established reimbursement and IDN relationships, though focused on arrhythmias rather than HF congestion.
  • AliveCor: Maker of KardiaMobile personal ECG devices with AI-based cardiac monitoring. Comparable as a connected, AI-driven cardiac monitoring company with both consumer and clinical channels targeting chronic cardiac condition management.

Broad incumbents

  • Edwards Lifesciences: A leading cardiovascular device company with hemodynamic monitoring expertise (Swan-Ganz catheters, FloTrac, Acumen IQ). Comparable as a broader incumbent in cardiac diagnostics and monitoring, though Edwards primarily operates in acute and surgical care settings rather than at-home RPM.
  • HeartFlow: AI-driven non-invasive cardiac diagnostics (FFR-CT) for coronary artery disease. Broader incumbent in non-invasive, imaging- and AI-based cardiac diagnostics used by cardiologists and health systems for decision support.
  • Withings: Connected consumer health devices including smart scales, blood pressure monitors, and sleep mats. Adjacent competitor in the connected home-health device category, though Withings targets general wellness rather than clinical HF management.

Emerging players

  • Sensydia: Develops non-invasive, AI-enabled cardiac function assessment platforms. Closely comparable to Bodyport in using non-invasive sensors plus proprietary algorithms to evaluate cardiac performance, though Sensydia targets pulmonary and cardiac acoustic biomarkers.
  • Cleerly: AI-driven coronary CT angiography analysis for plaque and ischemia assessment. Comparable as an emerging AI-native cardiac diagnostics company with strong health-system commercial traction and category-defining clinical evidence.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Bodyport social profiles

Digital presence

Bodyport compliance and trust

Trust signal

Compliance2 records

Bodyport financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bodyport leadership team

Management profile

Number of profiles

Profiles9 records

Bodyport funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bodyport M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bodyport

What does Bodyport do?

Bodyport develops and sells the FDA 510(k)-cleared Bodyport Cardiac Scale, a non-invasive connected scale that captures hemodynamic biomarkers through a patient's feet in under 30 seconds and transmits the data via cellular connection. It combines the hardware with the Congestion Index algorithm and a connected software platform (Care Portal for clinicians and Patient Portal for patients) to detect early signs of worsening heart failure and enable proactive in-home care.

Is Bodyport a public or private company?

Bodyport is a private company. It is classified as venture growth investor backed and is currently operating.

When was Bodyport founded?

Bodyport was founded in 2015. It employs 11 to 50 people.

Where is Bodyport based?

Bodyport is headquartered in San Francisco, United States, in the North America region.

How does Bodyport make money?

Two revenue lines are on record. Remote Patient Monitoring (RPM) Billing is the primary driver. The others are hardware Device Sales.

Who are Bodyport's main competitors?

Direct peers on record are Abbott, Vectorious Medical Technologies, Eko Health, iRhythm Technologies and AliveCor. Broad incumbents are Edwards Lifesciences, HeartFlow and Withings. Emerging players are Sensydia and Cleerly.

Does Bodyport have an API?

Yes. A robust API enables seamless integration with leading EHRs and third-party systems. The API supports RPM billing and enables clinical data transmission from the Bodyport Cardiac Scale to care teams.

What industry is Bodyport in?

Bodyport's product category is Remote Cardiac Monitoring. Its primary akta.pro industry code is HLACAPAI, Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration), with a secondary code of HLALAFAA, Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity).

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TrendHunter.comAt-Home Cardiac Monitoring ScalesSutter Health and Bodyport are introducing at-home cardiac monitoring scales through the Sutter Sync program for heart failure patients. The FDA-cleared Bodyport Cardiac Scale measures weight, fluid status, and cardiovascular indicators, with results entering Epic's electronic health records. The collaboration expands Sutter's digital chronic disease services and helps clinicians prioritize patients.Venture Capital Access OnlineBodyport Raises $11.2 Million in Series A Funding to Launch Virtual Cardiac ClinicBodyport announced the closing of an $11.2 million Series A funding round led by Boehringer Ingelheim Venture Fund, with participation from Playground Global and Initialized Capital. The company plans to use the capital to launch a virtual cardiac clinic and deepen health partnerships for its remote monitoring technology. Additionally, Bodyport announced a collaboration with Brigham and Women's Hospital to advance research in cardiovascular disease detection.Daily NewsBig Ideas: Matters of the heartSarah Smith and Corey Centen have launched Bodyport, a San Francisco-based startup developing sensor technology integrated into bathroom scales to predict heart disease through remote monitoring. The company is currently conducting its first clinical pilot with patients undergoing cardiopulmonary exercise testing to track hemodynamic changes. This development aims to shift cardiac care from reactive treatment to preventive management by detecting subtle health precursors in home settings.Daily Medical NewsScale using biosensor technology detects HF events more often than standard of careThe SCALE-HF 1 study demonstrated that a congestion index derived from Bodyport's biosensor scale predicts heart failure events more effectively than standard weight-based monitoring. The technology achieved double the sensitivity of traditional methods while significantly reducing false alert rates, allowing for earlier clinical interventions. Researchers anticipate this improvement will reduce hospitalizations and enhance workflow efficiency for care teams.tctmd.comSmart Scale Better at Predicting HF Events Than Weight-Based MonitoringResearch presented at THT 2024 indicates that the Bodyport smart scale, which uses a proprietary congestion index algorithm, predicts heart failure events with higher sensitivity and fewer alerts than traditional weight-based monitoring. The preliminary SCALE-HF 1 study of 329 participants showed the device detected twice as many events while generating significantly fewer physician alerts compared to standard weight tracking protocols.DAICBodyport Presents Preliminary Analysis of SCALE-HF 1 Study on Remote Heart Failure Monitoring at Technology and Heart Failure Therapeutics (THT) ConferenceBodyport Inc. presented preliminary data from its SCALE-HF 1 study at the THT Conference, demonstrating that its FDA-cleared biomarker-based cardiac scale detected twice as many heart failure events as the standard weight-based monitoring method. The technology generated nearly 40 percent fewer false alerts while achieving a 70% prediction rate for heart failure events compared to 35% for the standard of care.American Hospital Association3 Innovative Ways Providers Are Tackling Great ChallengesHealthcare providers are addressing challenges through street medicine, discharge lounges, and a cardiac scale. Street medicine teams now operate in over 60 U.S. cities, and discharge lounges save over 10,000 bed hours. Geisinger is piloting a fluid-guided care pathway using the Bodyport Cardiac Scale to detect heart failure earlier.MedCity NewsGeisinger Launches Heart Failure Monitoring Program Using Bodyport’s Smart ScaleGeisinger has launched a 12-month pilot program in partnership with Bodyport to monitor heart failure patients using the startup's smart cardiac scale. The initiative aims to evaluate whether remote monitoring of fluid buildup can improve case manager efficiency and reduce hospital readmissions among approximately 200 participants.PR NewswireStudy to Measure Accuracy of Unique Index for Early, Noninvasive Prediction of Worsening Heart FailureBodyport Inc. announced the launch of SCALE-HF, a multi-phase study to develop and validate the Heart Function Index (HFI), a composite algorithm using noninvasive hemodynamic biomarkers from the Bodyport Cardiac Scale to predict worsening heart failure events. The study, with results published in the journal Circulation: Heart Failure, will assess whether the HFI can provide earlier detection of fluid overload compared to standard weight-based monitoring, which currently affects over 6 million Americans with heart failure. Phase 2 of the study will generate pivotal data supporting Bodyport's application for FDA clearance of the HFI algorithm.Cardiovascular BusinessCardiac scale gains FDA clearance, putting patients 1 step away from a heart assessmentBodyport received U.S. Food and Drug Administration (FDA) clearance for its Cardiac Scale, a digital device designed to monitor fluid retention and support early intervention in heart failure management. The device utilizes sensors and algorithms to evaluate heart function and transmit data to care teams, having been cleared based on clinical studies conducted in the United States.